354 related articles for article (PubMed ID: 29515029)
21. Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth.
Huang J; Kang BH; Ishida E; Zhou T; Griesman T; Sheng Z; Wu F; Doria-Rose NA; Zhang B; McKee K; O'Dell S; Chuang GY; Druz A; Georgiev IS; Schramm CA; Zheng A; Joyce MG; Asokan M; Ransier A; Darko S; Migueles SA; Bailer RT; Louder MK; Alam SM; Parks R; Kelsoe G; Von Holle T; Haynes BF; Douek DC; Hirsch V; Seaman MS; Shapiro L; Mascola JR; Kwong PD; Connors M
Immunity; 2016 Nov; 45(5):1108-1121. PubMed ID: 27851912
[TBL] [Abstract][Full Text] [Related]
22. Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth.
Chukwuma VU; Kose N; Sather DN; Sapparapu G; Falk R; King H; Singh V; Lampley R; Malherbe DC; Ditto NT; Sullivan JT; Barnes T; Doranz BJ; Labranche CC; Montefiori DC; Kalams SA; Haigwood NL; Crowe JE
PLoS One; 2018; 13(12):e0209437. PubMed ID: 30566528
[TBL] [Abstract][Full Text] [Related]
23. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
Roben P; Moore JP; Thali M; Sodroski J; Barbas CF; Burton DR
J Virol; 1994 Aug; 68(8):4821-8. PubMed ID: 7518527
[TBL] [Abstract][Full Text] [Related]
24. Structural elements of primary CCR5-using HIV-1 gp120 proteins influencing sensitivity and resistance to the broadly neutralizing monoclonal antibody b12.
Sterjovski J; Churchill MJ; Ellett A; Wesselingh SL; Ramsland PA; Gorry PR
Virology; 2012 Oct; 432(2):394-404. PubMed ID: 22818780
[TBL] [Abstract][Full Text] [Related]
25. Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.
Townsley S; Li Y; Kozyrev Y; Cleveland B; Hu SL
J Virol; 2016 Jan; 90(2):829-41. PubMed ID: 26512079
[TBL] [Abstract][Full Text] [Related]
26. Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding.
Longo NS; Sutton MS; Shiakolas AR; Guenaga J; Jarosinski MC; Georgiev IS; McKee K; Bailer RT; Louder MK; O'Dell S; Connors M; Wyatt RT; Mascola JR; Doria-Rose NA
J Virol; 2016 Dec; 90(23):10574-10586. PubMed ID: 27654288
[TBL] [Abstract][Full Text] [Related]
27. HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design.
Bricault CA; Yusim K; Seaman MS; Yoon H; Theiler J; Giorgi EE; Wagh K; Theiler M; Hraber P; Macke JP; Kreider EF; Learn GH; Hahn BH; Scheid JF; Kovacs JM; Shields JL; Lavine CL; Ghantous F; Rist M; Bayne MG; Neubauer GH; McMahan K; Peng H; Chéneau C; Jones JJ; Zeng J; Ochsenbauer C; Nkolola JP; Stephenson KE; Chen B; Gnanakaran S; Bonsignori M; Williams LD; Haynes BF; Doria-Rose N; Mascola JR; Montefiori DC; Barouch DH; Korber B
Cell Host Microbe; 2019 Jan; 25(1):59-72.e8. PubMed ID: 30629920
[TBL] [Abstract][Full Text] [Related]
28. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
29. A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.
Li L; Wang XH; Williams C; Volsky B; Steczko O; Seaman MS; Luthra K; Nyambi P; Nadas A; Giudicelli V; Lefranc MP; Zolla-Pazner S; Gorny MK
Mol Immunol; 2015 Aug; 66(2):364-74. PubMed ID: 25965315
[TBL] [Abstract][Full Text] [Related]
30. An HIV-1 Env-Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes.
Chen Y; Wilson R; O'Dell S; Guenaga J; Feng Y; Tran K; Chiang CI; Arendt HE; DeStefano J; Mascola JR; Wyatt RT; Li Y
J Immunol; 2016 Nov; 197(10):3982-3998. PubMed ID: 27815444
[TBL] [Abstract][Full Text] [Related]
31. A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1.
Gach JS; Quendler H; Tong T; Narayan KM; Du SX; Whalen RG; Binley JM; Forthal DN; Poignard P; Zwick MB
PLoS One; 2013; 8(8):e72054. PubMed ID: 23991039
[TBL] [Abstract][Full Text] [Related]
32. Plasticity and Epitope Exposure of the HIV-1 Envelope Trimer.
Powell RLR; Totrov M; Itri V; Liu X; Fox A; Zolla-Pazner S
J Virol; 2017 Sep; 91(17):. PubMed ID: 28615206
[TBL] [Abstract][Full Text] [Related]
33. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
Li H; Zony C; Chen P; Chen BK
J Virol; 2017 May; 91(9):. PubMed ID: 28148796
[TBL] [Abstract][Full Text] [Related]
34. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
[TBL] [Abstract][Full Text] [Related]
35. Rational Engraftment of Quaternary-Interactive Acidic Loops for Anti-HIV-1 Antibody Improvement.
Liu Q; Zhang P; Miao H; Lin Y; Kwon YD; Kwong PD; Rikhtegaran-Tehrani Z; Seaman MS; DeVico AL; Sajadi MM; Lusso P
J Virol; 2021 May; 95(12):. PubMed ID: 33827946
[TBL] [Abstract][Full Text] [Related]
36. Broadly resistant HIV-1 against CD4-binding site neutralizing antibodies.
Zhou P; Wang H; Fang M; Li Y; Wang H; Shi S; Li Z; Wu J; Han X; Shi X; Shang H; Zhou T; Zhang L
PLoS Pathog; 2019 Jun; 15(6):e1007819. PubMed ID: 31194843
[TBL] [Abstract][Full Text] [Related]
37. Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies.
Gnanakaran S; Daniels MG; Bhattacharya T; Lapedes AS; Sethi A; Li M; Tang H; Greene K; Gao H; Haynes BF; Cohen MS; Shaw GM; Seaman MS; Kumar A; Gao F; Montefiori DC; Korber B
PLoS Comput Biol; 2010 Oct; 6(10):e1000955. PubMed ID: 20949103
[TBL] [Abstract][Full Text] [Related]
38. Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies.
Shen G; Upadhyay C; Zhang J; Pan R; Zolla-Pazner S; Kong XP; Hioe CE
PLoS One; 2015; 10(10):e0141233. PubMed ID: 26491873
[TBL] [Abstract][Full Text] [Related]
39. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
[TBL] [Abstract][Full Text] [Related]
40. Identification of Near-Pan-neutralizing Antibodies against HIV-1 by Deconvolution of Plasma Humoral Responses.
Sajadi MM; Dashti A; Rikhtegaran Tehrani Z; Tolbert WD; Seaman MS; Ouyang X; Gohain N; Pazgier M; Kim D; Cavet G; Yared J; Redfield RR; Lewis GK; DeVico AL
Cell; 2018 Jun; 173(7):1783-1795.e14. PubMed ID: 29731169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
